News

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to…

2 years ago

BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants

VANCOUVER, BC / ACCESSWIRE / December 8, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) announces that, further…

2 years ago

MEDFINITI Introduces HemWell MD: Along with its Breakthrough in Hemorrhoid Technology “HemWell”

TAMPA, FL / ACCESSWIRE / December 8, 2023 / MEDFINITI B.V. and its U.S. subsidiaries, MEDFINITI, Inc. and HemWell MD…

2 years ago

Skye Bioscience Responds to OTC Markets Promotional Policy

San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical…

2 years ago

Science Formulation and NMN.ca Unite to Bring the Latest NMN Supplement Insights to the Public

Vancouver, British Columbia--(Newsfile Corp. - December 8, 2023) - NUNMN's Science Formulation, a prominent online store specializing in NMN (Nicotinamide…

2 years ago

Cosmos Health to Participate at Capital Link’s ‘Invest in Greece’ Forum in New York

CHICAGO, IL / ACCESSWIRE / December 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 years ago

GE HealthCare Announces Cash Dividend for Fourth Quarter of 2023

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per…

2 years ago

Revive Recovery and Detox Services Clarifies NO AFFILIATION With Revive Premier Treatment Center

LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / Revive Recovery and Detox Services, an addiction treatment center located…

2 years ago

Update on Reverse Acquisition – PMD Completes Private Placement and Major Shareholder Receives Exemption from Mandatory Bid Requirements

STOCKHOLM, SE / ACCESSWIRE / December 8, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) Promore Pharma AB (publ) (the "Company" or "Promore")…

2 years ago